News | March 11, 2011

FDA Grants Special Protocol Approval for Trial of Coronary Disease Radiotracer

March 11, 2011 – U.S. Food and Drug Administration (FDA) and Lantheus Medical Imaging Inc. today reached agreement on a phase 3 clinical trial design to assess myocardial perfusion using flurpiridaz F18 positron emission tomography (PET) imaging in patients with suspected or known coronary artery disease (CAD).

The company and the FDA worked out a special protocol assessment for the trial and the planned analysis of the data. The company plans to initiate the first of two planned phase 3 trials in the second quarter of 2011.

“The SPA agreement is a significant milestone in the development of flurpiridaz F18 and provides us with a clearly defined path forward for the phase 3 program,” said Don Kiepert, president and CEO of Lantheus Medical Imaging. “We thank the FDA for their timely review and approval of this SPA and look forward to initiating the phase 3 program and building on the clinical trial results to date for this agent. We believe that flurpiridaz F18 can improve the diagnosis and evaluation of coronary artery disease, ultimately reducing the need for additional medical tests and procedures.”

Flurpiridaz F18 has completed a phase 2 clinical trial, and analysis of the full data set will be presented at the Nuclear Cardiology and Cardiac CT Conference, scheduled May 15-18 in Amsterdam. Preliminary phase 2 data were presented at the annual meeting of the Society of Nuclear Medicine (SNM) in June 2010. These data showed that PET imaging with flurpiridaz F18 provided better image quality than technetium-99m sestamibi single photon emission computed tomography (SPECT), the current standard for the noninvasive detection of CAD. No serious adverse events attributable to flurpiridaz F18 injection were reported in phase 1 or phase 2 clinical trials. Numerous other abstracts based on single-center evaluation of flurpiridaz F18 data were presented at various medical conferences in 2010.

“The results of the phase 2 study with flurpiridaz F18 are promising and we look forward to presenting the full data analysis later this year and initiating the phase 3 program,” said Dana S. Washburn, M.D., vice president, clinical development and medical affairs at Lantheus. “Our phase 3 program demonstrates our ongoing commitment to developing first-in-class imaging tools to advance patient care, and we remain dedicated to investigating the potential of PET technology for evaluating cardiovascular disease.”

The phase 3 clinical development program will include two open-label trials designed to assess myocardial perfusion using PET imaging of flurpiridaz F18 in approximately 1,350 patients with suspected or known CAD at approximately 100 clinical trial sites, including locations in the United States, Canada, Europe and South America. The primary objective of the study will be to assess the diagnostic efficacy (sensitivity and specificity) of flurpiridaz F18 injection PET myocardial perfusion imaging (MPI), compared with SPECT MPI in the detection of significant coronary artery disease.

A SPA is an agreement between the sponsor and the FDA indicating that the sponsor’s proposed trial protocol, including clinical endpoints and statistical analyses, are acceptable to support regulatory approval of the treatment being evaluated. FDA approval for the product is dependent on efficacy results, adverse event profiles and an evaluation of the benefit/risk of a treatment as demonstrated in the clinical trials

Flurpiridaz F18 Injection

Flurpiridaz F18 injection, a fluorine 18-labeled agent that binds to mitochondrial complex 1 (MC-1), is designed to be a new myocardial perfusion PET imaging agent for the diagnosis of coronary artery disease (CAD). PET imaging with flurpiridaz F18 has the potential to be a new clinical tool for the evaluation of myocardial perfusion that may better evaluate patients with known or suspected CAD. CAD is the most common form of heart disease, affecting approximately 16.8 million people in the United States.

For more information: www.lantheus.com

Related Content

Study Demonstrates First Human Application of Novel PET Tracer for Prostate Cancer

Transaxial 11Csarcosine hybrid PET/CT showed a (triangulated) adenocarcinoma in the transition zone of the anterior right prostate gland on PET (A), CT (B), and a separately obtained T2?weighted MR sequence (C) with resulting PET/MRI registration (D). Image courtesy of M. Piert et al., University of Michigan, Ann Arbor, Mich.

News | Radiopharmaceuticals and Tracers | August 16, 2017
In the featured translational article in the August issue of The Journal of Nuclear Medicine, researchers at the...
PET/CT Tracer Identifies Vulnerable Lesions in Non-Small Cell Lung Cancer Patients

Example of a patient with an upper left lung NSCLC: A: FDG; B: FDG PET/CT; C: Planning radiotherapy based on FDG (66Gy) with BTVm (GTV), CTV and PTV; D: PET FMISO E: FMISO PET/CT; F: boost based on the FMISO PET (76Gy) with BTVh (biological hypoxic target volume) and PTV boost. Credit: QuantIF – LITIS EA 4108 – FR CNRS 3638, Henri Becquerel Cancer Center, Rouen, France

News | PET-CT | July 14, 2017
July 14, 2017 — Fluorine-18 (18F)-fluoromisonidazole (FMISO) is a positron emission tomography (PET)...
Novel PET Tracer Detects Small Blood Clots

PET images (MIP 0-60 min) of three Cynomolgus monkeys. Strong signals are detected at the sites where inserted catheters had roughened surfaces. Almost no other background signal is visible. Only accumulation in the gallbladder becomes visible at the bottom of the image. Credit: Piramal Imaging GmbH, Berlin Germany.

News | PET Imaging | July 07, 2017
July 7, 2017 — Blood clots in veins a
Dual-Agent PET/MR With Time of Flight Detects More Cancer

Tc-99m MDP bone scan (left) is negative for osseous lesions. NaF/FDG PET/MRI (right and second slide) confirms absence of bone metastases, but shows liver metastases. Image courtesy of Stanford University.

News | PET-MRI | June 20, 2017
Simultaneous injections of the radiopharmaceuticals fluorine-18 fluorodeoxyglucose (18F-FDG) and 18F-sodium fluoride (...

While subject No. 1 (left) was judged as positive for both the neuronal injury and the amyloid load biomarker, both Alzheimer's disease biomarkers were negative in subject No. 2 (right). Image courtesy of Henryk Barthel et al., University Hospital Leipzig, Leipzig, Germany

News | PET Imaging | June 14, 2017
More people die of Alzheimer's disease than prostate and breast cancer combined. Identifying the disease before major...
News | Clinical Study | June 09, 2017
The milestone Imaging Dementia — Evidence for Amyloid Scanning (IDEAS) Study is working with government and academic...
Lantheus and GE Healthcare Sign Agreement for Worldwide Development, Commercialization of Flurpiridaz F-18
News | Radiopharmaceuticals and Tracers | May 22, 2017
May 22, 2017 — Lantheus Holdings Inc., parent company of Lantheus Medical Imaging Inc., and GE Healthcare announced t
FALCON Trial of Fluciclovine PET/CT Imaging Stops Recruitment after Successful Interim Analysis
News | Radiopharmaceuticals and Tracers | May 15, 2017
Blue Earth Diagnostics announced that the Trial Steering Committee recommended further recruitment be stopped in the...
low-dose lung CT scan

An example of a low-dose CT scan of the lungs, showing lung cancer. Image courtesy of Toshiba.

Feature | Lung Cancer | May 05, 2017 | Alison Grimes
The term mesothelioma was coined in 1909, just a few years after the introduction of medical X-ray imaging.
Australian Team Finds New Method for Producing PET Radiotracers in Higher Radiochemical Yields
News | Radiopharmaceuticals and Tracers | April 28, 2017
April 28, 2017 — Researchers at the Australian Nuclear Science and Technology Organisation (ANSTO) have led the devel
Overlay Init